[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636674":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":33,"responsibleParty":50,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":19,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":19,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":19,"overallStatus":75,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Post-Focal Therapy Flotufolastat F18PET","EXPERIMENTAL","Post-Focal Therapy Flotufolastat F18 PET",[13],"Diagnostic Test: Flotufolastat F18 PET",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Flotufolastat F18 PET",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Michael Daneshvar, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":19},"University of California Irvine Medical Center",[34],{"facility":35,"status":19,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Chao Family Comprehensive Cancer Center, University of California, Irvine","Orange","California","92868","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-117.85311,33.78779,{"lat":45,"lon":44},[48],{"name":22,"role":28,"phone":49,"phoneExt":19,"email":30},"877-827-8839",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Michael Daneshvar","Assistant Professor of Clinical Urology",[54],{"name":55,"class":56},"Blue Earth Diagnostics","INDUSTRY","100636674","phase-2-utilization-of-flotufolastat-18f-pet-for-post-focal-therapy-prostate-cancer-evaluation-100636674",false,"NCT07568756","Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation","Inclusion Criteria:\n\n* Age 18 years or greater at time of consent\n* Prostate adenocarcinoma (no other histologic subtypes allowed)\n* Prostate Cancer planned to be treated by focal therapy (e.g. cryotherapy, HIFU, or NanoKnife)\n* Multiparametric-MRI imaging planned\n* Planned pre- and post- treatment MRI-fusion biopsy\n\nExclusion Criteria:\n\n* Prior treatment for any prostate malignancy (e.g. radiation, focal therapy, or systemic therapy)\n* Genomic classifiers (e.g. Decipher) signifying intermediate or high-risk disease\n* PSA \\>10\n* High-risk prostate cancer (diagnosed by biopsy)\n* Bilateral prostatic lobe disease","MALE","18 Years",{"count":66,"type":67},60,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.",[73,74],"Prostate Adenocarcinoma","Prostate Cancer","NOT_YET_RECRUITING","2026-04-28",{"date":78,"type":79},"2026-05-06","ACTUAL",{"date":81,"type":67},"2026-05",{"date":83,"type":67},"2029-05",{"name":5,"class":6},1]